Sionna Therapeutics, Inc. (NASDAQ:SION) Given Consensus Recommendation of “Hold” by Analysts

Sionna Therapeutics, Inc. (NASDAQ:SION) has been given a consensus recommendation of “Hold” by the thirteen brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $42.2222.

Several analysts have recently weighed in on the stock. Wedbush lowered shares of Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 price objective for the company. in a research note on Monday, August 10th. JonesTrading lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Raymond James Financial cut shares of Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a report on Monday, August 10th. BTIG Research downgraded shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 10th. Finally, Royal Bank Of Canada upgraded shares of Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price objective on the stock in a report on Monday, August 10th.

Sionna Therapeutics Stock Performance

Shares of SION stock opened at $7.85 on Friday. Sionna Therapeutics has a fifty-two week low of $4.01 and a fifty-two week high of $54.97. The stock has a 50 day simple moving average of $26.25 and a two-hundred day simple moving average of $34.59. The company has a market cap of $354.90 million, a P/E ratio of -3.60 and a beta of 0.89.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). On average, research analysts predict that Sionna Therapeutics will post -2.55 earnings per share for the current year.

Insider Transactions at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director directly owned 2,469,959 shares of the company’s stock, valued at $110,802,360.74. This trade represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 403,524 shares of company stock valued at $18,250,367 over the last ninety days. 5.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sionna Therapeutics

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new stake in Sionna Therapeutics in the 1st quarter valued at $667,000. Woodline Partners LP acquired a new position in Sionna Therapeutics during the first quarter worth $837,000. Geode Capital Management LLC lifted its stake in shares of Sionna Therapeutics by 113.4% in the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock valued at $5,020,000 after buying an additional 153,712 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Sionna Therapeutics in the second quarter valued at $307,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Sionna Therapeutics during the second quarter valued at about $118,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.